Rearming the body’s immune system to fight cancer

We’re developing more precise and more accessible treatment alternatives for patients with solid cancers

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer.

Learn more about us

Some of our partners

Latest news

Cartherics’ CEO discusses the future of solid tumour therapy

By Karen Loudon / February 15, 2024
Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the...
Read More

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

By Karen Loudon / February 12, 2024
There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when...
Read More

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

By Karen Loudon / February 1, 2024
Melbourne, Australia, 1 February 2024 –  Cartherics Pty Ltd ("Cartherics" or "Company"), a biotechnology company developing immune cell therapies for the...
Read More
1 3 4 5 6 7 59